CMV-Vector HBV Vaccine for Chronic Infection Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HBV vaccines are ineffective in treating chronic infections, and there is a need for immunotherapies that can induce effective immune responses to eliminate HBV, particularly in individuals with different genotypes, as existing treatments fail to clear the virus and have severe side effects.
Innovation Solution
Development of a polypeptide-based vaccine using cytomegalovirus (CMV) vectors encoding HBV episensus antigens, such as those with amino acid sequences from SEQ ID NOs:1-36, to stimulate CD8+ T cell responses and generate an immune response against HBV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HBV vaccines are used, then prophylactic protection is provided, but they are ineffective in treating chronic infections
Solution Approach 1:
The vaccine system is segmented into multiple components: CMV viral vectors expressing different HBV antigens (HBsAg, HBeAg, HBcAg), enabling targeted delivery of specific antigenic determinants to elicit comprehensive immune responses against chronic infection
Solution Approach 2:
Cytomegalovirus (CMV) vectors serve as intermediary carriers to deliver HBV antigens into host cells, utilizing CMV's efficient cellular entry and nuclear delivery mechanisms to ensure robust antigen expression and sustained immune stimulation
2Reliability
If antiviral therapies are used, then viral replication is inhibited, but they rarely clear the virus and require life-long treatment
Solution Approach 1:
The vaccine converts the persistent nature of CMV infection, which is typically harmful, into a beneficial sustained antigen delivery system. CMV's ability to establish lifelong persistence is harnessed to provide continuous antigen expression, maintaining immune pressure without requiring lifelong antiviral medication
Solution Approach 2:
The CMV vector system provides self-sustaining antigen delivery through its unique replication-competent nature, allowing continuous production and presentation of HBV antigens without external intervention, thereby maintaining immune activation autonomously
3Reliability
If interferon-α therapy is used, then the innate immune system is stimulated, but severe side effects occur
Solution Approach 1:
The CMV vector acts as an intermediary that indirectly stimulates the immune system through antigen presentation rather than direct immune activation. This indirect approach achieves immune system engagement without the severe side effects associated with direct interferon-α administration
Solution Approach 2:
Instead of using interferon-α itself, the vaccine uses CMV vectors that copy and express HBV antigens, allowing the immune system to recognize and respond to viral determinants in a more controlled and tolerable manner
Data Source
AI summary
Isolated polynucleotides and polypeptides, and hepatitis B virus (HBV) vaccines comprising the same. Viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area.